Resources – Lifsa Pharma

The Future of Generic Drug Manufacturing: Overcoming Challenges and Seizing Opportunities in 2025

Introduction: A Pivotal Year for Pharmaceutical Manufacturing The pharmaceutical industry stands at a critical juncture in 2025. With AI driving 30% of new drug discoveries, $265 billion in care services shifting to home settings, and regulatory initiatives like FDA PreCheck streamlining domestic manufacturing, generic pharmaceutical companies face both unprecedented opportunities and complex challenges. At LifSa Pharma, we’ve witnessed firsthand how […]

The Strategic Acquisition of Marplan: A Case Study in Pharmaceutical Value Creation

Executive Summary Strategic acquisitions continue to shape the landscape of the U.S. pharmaceutical industry in 2024 and 2025, particularly in the area of legacy treatments for complex conditions. Among these, Marplan® (isocarboxazid) stands out as a unique, FDA-approved monoamine oxidase inhibitor (MAOI) prescribed for certain patients with depression. This article explores the implications of such acquisitions and […]